Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

다국어 초록 (Multilingual Abstract)

Background: Cardiovascular risk remains increased despite optimal low density lipoprotein cholesterol (LDL-C) level induced by intensive statin therapy. Therefore, recent guidelines recommend non-high density lipoprotein cholesterol (non-HDL-C) as a secondary target for preventing cardiovascular events. The aim of this study was to assess the efficacy and tolerability of omega-3 fatty acids (OM3-FAs) in combination with atorvastatin compared to atorvastatin alone in patients with mixed dyslipidemia.
Methods: This randomized, double-blind, placebo-controlled, parallel-group, and phase III multicenter study included adults with fasting triglyceride (TG) levels ≥200 and <500 mg/dL and LDL-C levels <110 mg/dL. Eligible subjects were randomized to ATOMEGA (OM3-FAs 4,000 mg plus atorvastatin calcium 20 mg) or atorvastatin 20 mg plus placebo groups. The primary efficacy endpoints were the percent changes in TG and non-HDL-C levels from baseline at the end of treatment.
Results: After 8 weeks of treatment, the percent changes from baseline in TG (–29.8% vs. 3.6%, P<0.001) and non-HDL-C (–10.1% vs. 4.9%, P<0.001) levels were significantly greater in the ATOMEGA group (n=97) than in the atorvastatin group (n=103). Moreover, the proportion of total subjects reaching TG target of <200 mg/dL in the ATOMEGA group was significantly higher than that in the atorvastatin group (62.9% vs. 22.3%, P<0.001). The incidence of adverse events did not differ between the two groups.
Conclusion: The addition of OM3-FAs to atorvastatin improved TG and non-HDL-C levels to a significant extent compared to atorvastatin alone in subjects with residual hypertriglyceridemia.

참고문헌 (Reference)

• 1 Singh AK, "Triglyceride and cardiovascular risk : a critical appraisal" 20 : 418-428, 2016
• 2 Hegele RA, "The polygenic nature of hypertriglyceridaemia : implications for definition, diagnosis, and management" 2 : 655-666, 2014
• 3 Elam M, "The ACCORD-Lipid study : implications for treatment of dyslipidemia in type 2 diabetes mellitus" 6 : 9-20, 2011
• 4 Yuki T, "Synergistic favorable effect of eicosapentaenoic acid and statin on atherosclerosis" 29 : 2147-2152, 2018
• 5 Notarnicola M, "Synergic effect of eicosapentaenoic acid and lovastatin on gene expression of HMGCoA reductase and LDL receptor in cultured HepG2 cells" 9 : 135-, 2010
• 6 Davidson MH, "Results of the National Cholesterol Education(NCEP)Program Evaluation ProjecT Utilizing Novel E-Technology(NEPTUNE)II survey and implications for treatment under the recent NCEP Writing Group recommendations" 96 : 556-563, 2005
• 7 Wong ND, "Residual atherosclerotic cardiovascular disease risk in statin-treated adults : The Multi-Ethnic Study of Atherosclerosis" 11 : 1223-1233, 2017
• 8 Chan DC, "Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia" 51 : 2377-2386, 2002
• 9 이명하, "Prevalence of Dyslipidemia among Korean Adults: Korea National Health and Nutrition Survey 1998-2005" 대한당뇨병학회 36 (36): 43-55, 2012
• 10 Wilson PW, "Prediction of coronary heart disease using risk factor categories" 97 : 1837-1847, 1998
• 11 Yan JH, "Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials" 97 : e12271-, 2018
• 12 Kastelein JJ, "Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia : the EpanoVa fOr Lowering Very high triglyceridEs(EVOLVE)trial" 8 : 94-106, 2014
• 13 Maki KC, "Omega-3 fatty acids for the treatment of elevated triglycerides" 4 : 425-437, 2009
• 14 Lepretti M, "Omega-3 fatty acids and insulin resistance : focus on the regulation of mitochondria and endoplasmic reticulum stress" 10 : E350-, 2018
• 15 Bowen KJ, "Omega-3 fatty acids and cardiovascular disease: are there benefits?" 18 : 69-, 2016
• 16 Davidson MH, "Omega-3 fatty acids : new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid" 24 : 467-474, 2013
• 17 Skulas-Ray AC, "Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia" 9 : 1237-1248, 2008
• 18 Puri R, "Non-HDL cholesterol and triglycerides : implications for coronary atheroma progression and clinical events" 36 : 2220-2228, 2016
• 19 Robinson JG, "Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk" 53 : 316-322, 2009
• 20 LaRosa JC, "Intensive lipid lowering with atorvastatin in patients with stable coronary disease" 352 : 1425-1435, 2005
• 21 Miller M, "Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial" 51 : 724-730, 2008
• 22 Davidson MH, "Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study" 29 : 1354-1367, 2007
• 23 Ballantyne CM, "Efficacy and safety of eicosapentaenoic acid ethyl ester(AMR101)therapy in statin-treated patients with persistent high triglycerides(from the ANCHOR study)" 110 : 984-992, 2012
• 24 Kim CH, "Efficacy and safety of adding omega-3 fatty acids in statin-treated patients with residual hypertriglyceridemia : ROMANTIC(Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a randomized, double-blind, and placebo-controlled trial" 40 : 83-94, 2018
• 25 Chen C, "Effects of omega-3 fatty acid supplementation on glucose control and lipid levels in type 2 diabetes : a meta-analysis" 10 : e0139565-, 2015
• 26 Dunbar RL, "Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia : a randomized, controlled, double-blind trial" 14 : 98-, 2015
• 27 Eussen SR, "Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction" 33 : 1582-1588, 2012
• 28 Scott R, "Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study" 32 : 493-498, 2009
• 29 Yokoyama M, "Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients(JELIS) : a randomised open-label, blinded endpoint analysis" 369 : 1090-1098, 2007
• 30 Yang K, "Effectiveness of omega-3 fatty acid for polycystic ovary syndrome : a systematic review and meta-analysis" 16 : 27-, 2018
• 31 Jacobo-Cejudo MG, "Effect of n-3 polyunsaturated fatty acid supplementation on metabolic and inflammatory biomarkers in type 2 diabetes mellitus patients" 9 : E573-, 2017
• 32 Nosaka K, "Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes : 1-year outcomes of a randomized controlled study" 228 : 173-179, 2017
• 33 Tirosh A, "Changes in triglyceride levels and risk for coronary heart disease in young men" 147 : 377-385, 2007
• 34 Bhatt DL, "Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia" 380 : 11-22, 2019
• 35 Haffner SM, "Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes" 263 : 2893-2898, 1990
• 36 이명원, "Beneficial Effects of Omega-3 Fatty Acids on Low Density Lipoprotein Particle Size in Patients with Type 2 Diabetes Already under Statin Therapy" 대한당뇨병학회 37 (37): 207-211, 2013
• 37 Ng TW, "Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men" 16 : 519-526, 2014
• 38 Jellinger PS, "American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease" 23 : 1-87, 2017
• 39 Catapano AL, "2016 ESC/EAS guidelines for the management of dyslipidaemias" 37 : 2999-3058, 2016